NCT01877382 2025-03-27
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
Clinical Trials
6 trialsNCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT05932667 2023-12-21
DEMETER
Institut Curie
Phase 2 Terminated
NCT03671564 2023-11-07
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT03552029 2022-05-20
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Terminated